![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lista de categorías
AlcoholismoAlzheimer Y ParkinsonAnalgésicosAntialérgicasAntibióticosAnticonceptivosAnticonvulsivosAntidepresivosAntifúngicosAntiinflamatoriosAntiparasitariosAntiviralesArtritisAsmaCirugíaColesterolCuidados De La PielCuidados De Los OjosCáncerDiabetesDisfunción EréctilDiuréticosEnfermedad CardiovascularEnfermedades GastrointestinalesEnfermedades GenitourinariasEnfermedades NeurológicasMedicamentos V I HMigrañasOsteoporosisPresión ArterialPérdida De PesoRelajantes MuscularesSalud FemeninaSalud MasculinaTracto RespiratorioTrastornos Mentales 23 May 2012 16:34:46
Merck CEO assures shareholders there is life after death of Singulair patentMerck CEO assures shareholders there is life after death of Singulair patent FiercePharma It also paid $41.1 billion several years ago for Schering-Plough to help cushion the patent loss blow, gaining full rights to cholesterol drugs Vytorin and Zetia , as well as its current No. 2 seller, Remicade.
23 May 2012 15:03:22
CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate ...CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate ... MarketWatch (press release) The FDA issued an early communication after results from the ENHANCE trial indicated that adding ezetimibe (known as either Zetia or the ezetimibe-simvastatin combination, Vytorin) to a treatment regimen including simvastatin did not appear to improve ...
23 May 2012 15:01:38
CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate ...CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate ... PR Newswire (press release) The FDA issued an early communication after results from the ENHANCE trial indicated that adding ezetimibe (known as either Zetia or the ezetimibe-simvastatin combination, Vytorin) to a treatment regimen including simvastatin did not appear to improve ...
22 May 2012 15:37:31
Merck: Manufacturing Portfolio Health With Dividend IncomeMerck: Manufacturing Portfolio Health With Dividend Income Seeking Alpha Two of their major revenue generators, Zetia and Vytorian, will continue to be available only through Merck until 2017. The company was successfully able to thwart Mylan (MYL) from creating generic versions of these medications before the patents that ...
20 May 2012 21:09:37
Glenmark's different route to US drug marketGlenmark's different route to US drug market Business Standard It also wants to launch a low-cost version of a major drug, Zetia by Merck, in 2017-17 in the US, with similar rights to tap a significant share in the market. The drug has a market size of around $1.4 billion. Glenmark is already enjoying marketing ...
30 Apr 2012 22:41:49
Why the Dow's Barely Budging This MorningWhy the Dow's Barely Budging This Morning msnbc.com Merck rose more than 2% after a court ruling that confirmed the drugmaker's patents on Zetia and Vytorin. Generic-drug maker Mylan had sought to produce a copy of the drugs prior to their expiration in 2017. With Merck already facing patent-cliff ...
30 Apr 2012 19:13:58
Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks;Merck wins patent fight on Zetia , Vytorin; Fitch warns of 'pure pharma' risks; FiercePharma Article Follow FiercePharma » A US court upheld Merck's ($MRK) patent on the active ingredient ezetimibe, marketed as the cholesterol-lowering Zetia and in the combo cholesterol pill Vytorin. Report » Fitch Ratings says drugmakers that focus purely ... Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute Merck wins pharmaceutical sales rights to two blockbuster drugs through 2017
30 Apr 2012 18:48:40
What Could Move the Dow This WeekWhat Could Move the Dow This Week msnbc.com Meanwhile, rival Merck got some good news Friday, when a court upheld a patent on its cholesterol drugs, Zetia and Vytorin. The two drugs contributed more than $1 billion in sales in the company's first quarter. Meanwhile, Kraft baffled market-watchers ...
|
|
Choose Your language:
Site search
Testimonios de nuestros clientes
¡BUENOS DÍAS!
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Bestsellers|Nuestra política|F.A.Q.|Testimonios de nuestros clientes|Contacto|Sitemap |
|
|
|
|
| |